NASDAQ: AUGXAugmedix Inc Stock
$2.85+0.01 (+0.35%)
Updated Apr 24, 2024
AUGX Price
$2.85
Fair Value Price
$2.85
Market Cap
$138.91M
52 Week Low
$2.70
52 Week High
$6.25
P/E
-6.48x
P/B
5.96x
P/S
5.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$44.86M
Earnings
-$19.17M
Gross Margin
48%
Operating Margin
-37.39%
Profit Margin
-42.7%
Debt to Equity
1.86
Operating Cash Flow
-$15M
Beta
1.06
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AUGX Overview
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the U.S. Its platforms (Augmedix Live and Augmedix Notes) offer pre-visit documentation (pre-charting and digitization of previous records/patient history), during-visit documentation, and after-visit summaries and post-visit documentation. Clinicians cab access its applications through mobile devices. The company was founded in 2013 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AUGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUGX ($2.85) is undervalued by 0.02% relative to our estimate of its Fair Value price of $2.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AUGX ($2.85) is not significantly undervalued (0.02%) relative to our estimate of its Fair Value price of $2.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AUGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AUGX due diligence checks available for Premium users.
Be the first to know about important AUGX news, forecast changes, insider trades & much more!
AUGX News
Valuation
AUGX fair value
Fair Value of AUGX stock based on Discounted Cash Flow (DCF)
Price
$2.85
Fair Value
$2.85
Undervalued by
0.02%
AUGX ($2.85) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AUGX ($2.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AUGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AUGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.48x
Industry
72.14x
Market
41.27x
AUGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.96x
Industry
3.39x
AUGX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUGX's financial health
Profit margin
Revenue
$12.7M
Net Income
-$4.5M
Profit Margin
-35.4%
AUGX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AUGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.7M
Liabilities
$43.4M
Debt to equity
1.86
AUGX's short-term assets ($56.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUGX's short-term assets ($56.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AUGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$973.0k
Investing
-$1.2M
Financing
$26.4M
AUGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AUGX vs Health Information Service Stocks
Augmedix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.